Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis

Reducing costs while enhancing quality of care in MS: Table

(2016) Ilya Kister et al.   NEUROLOGY

Epidemiology of multiple sclerosis

(2016) E. Leray et al.   REVUE NEUROLOGIQUE

Prediction of disability progression in fingolimod-treated patients

(2015) Simona Lattanzi et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

(2015) Emmanuelle Le Page et al.   LANCET

Oral versus intravenous steroids in multiple sclerosis relapses – a perennial question?

(2014) Jeremy Chataway   Multiple Sclerosis Journal

Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses

(2014) L Grau-López et al.   Multiple Sclerosis Journal

Multiple sclerosis, solitary sclerosis or something else?

(2014) Simona Lattanzi et al.   Multiple Sclerosis Journal

A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

(2013) C Ramo-Tello et al.   Multiple Sclerosis Journal

Treatment of Acute Relapses in Multiple Sclerosis

(2012) Regina Berkovich   Neurotherapeutics

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS

(2009) V. Martinelli et al.   NEUROLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE